Faruqi and Faruqui, LLP Logo
Share this page

Recro Pharma, Inc. (REPH)

NASDAQ:REPH

Summary

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Recro Pharma, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Recro Pharma, Inc. (“Recro” or the “Company”) (NASDAQ:REPH) of the July 30, 2018 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Recro stock or options between July 31, 2017 through May 23, 2018 and would like to discuss your legal rights, please fill out the form below. There is no cost or obligation to you.You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

The lawsuit has been filed in the U.S. District Court for the Eastern District of Pennsylvania on behalf of all those who purchased Recro securities between July 31, 2017 through May 23, 2018 (the “Class Period”).  The case, ALBERICI v. RECRO PHARMA, INC. et al, No. 18-cv-02279 was filed on May 31, 2018, and has been assigned to Judge Michael M. Baylson.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose the Company’s lead product, IV meloxicam, lacked supporting clinical data to show sufficient clinical benefits to receive U.S. Food and Drug Administration (“FDA”) approval.

Specifically, on May 24, 2018, Recro issued a press release entitled “Recro Pharma Receives Complete Response Letter from the FDA,” disclosing that the FDA had declined to approve Recro’s New Drug Application for IV meloxicam. The FDA stated that the data from ad hoc analyses and selective secondary endpoints suggest that the drug’s analgesic effect does not meet the expectations of the FDA.

After the announcement, Recro’s share price fell from $12.42 per share on May 23, 2018 to a closing price of $5.55 on May 24, 2018—a $6.87 or a 55.31% drop.

Contact Us

To contact Faruqi & Faruqi, LLP please call (877) 247-4292 or (212) 983-9330, or please
fill out the form below and a Firm representative will contact you.

  • Case:
    Recro Pharma, Inc. (REPH)
  •    

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330

Email:

Case Details

Date:

  • 06/01/2018

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.